Faisal S. BinHumaid

Jan 31, 2024 | europeanurology.com | Anshita Goel |Naheema S. Gordon |Faisal S. BinHumaid |Ben Abbotts |K.K. Cheng |Maurice P. Zeegers | +8 more

Detection of circulating tumour DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) pre-empts imaging-detected metastatic relapse [], is associated with worse outcomes [], and implies a response to adjuvant immune checkpoint inhibition []. Typically, ctDNA detection relies on sequencing of tumour tissue and the development of patient-specific ctDNA assays []; such assays may be challenging to implement in routine health care.